Disease · EFO_1001865

ventilator-associated pneumonia

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. ventilator-associated pneumonia. Diseases, record EFO_1001865. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_1001865

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: ventilator-associated pneumonia; Open Targets
Open Targets ID: EFO_1001865; Open Targets
Other names: Pneumonia, Ventilator-Associated, VAP, ventilator-acquired pneumonia; Open Targets
MeSH: D053717; MeSH
Highest stage of its drugs: Approval, for 6 of its 50 drugs, from EMA Human Drugs and TTD; Open Targets

Drugs50

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
MEROPENEM	CHEMBL127	Small molecule	Approval	EMA Human Drugs	12	11	11	Drugs and targets
DORIPENEM	CHEMBL491571	Small molecule	Approval	EMA Human Drugs, at withdrawal	5	4	4	Drugs and targets
CEFEPIME	CHEMBL186	Small molecule	Approval	EMA Human Drugs	2	1	1	Drugs and targets
CEFIDEROCOL	CHEMBL3989974	Small molecule	Approval	TTD	2	1	1	Drugs and targets
ENMETAZOBACTAM	CHEMBL4458276	Small molecule	Approval	EMA Human Drugs	1	0	0	Drugs and targets
VABORBACTAM	CHEMBL3317857	Small molecule	Approval	EMA Human Drugs	1	0	0	Drugs and targets
AMIKACIN	CHEMBL177	Small molecule	Phase 3	ClinicalTrials.gov	7	7	7	Drugs and targets
COLISTIN	CHEMBL6067481		Phase 3	ClinicalTrials.gov	6	6	6	Drugs and targets
AVIBACTAM	CHEMBL1689063	Small molecule	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
CEFTAZIDIME	CHEMBL44354	Small molecule	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets

1 to 10 of 50

See all 50 drugs

Targets21

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
GABRA1	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2554	Drugs and targets
GABRA2	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2555	Drugs and targets
GABRA3	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2556	Drugs and targets
GABRA4	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2557	Drugs and targets
GABRA5	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2558	Drugs and targets
GABRA6	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2559	Drugs and targets
GABRB1	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2560	Drugs and targets
GABRB2	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2561	Drugs and targets
GABRB3	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2562	Drugs and targets
GABRD	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2563	Drugs and targets

1 to 10 of 21

See all 21 targets

Trials52

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01808092	A Study Comparing Ceftazidime-Avibactam Versus Meropenem in Hospitalized Adults With Nosocomial Pneumonia	Phase 3	969	2017-02-03	Nosocomial Pneumonia (NP), Ventilator-associated Pneumonia (VAP)	AVIBACTAM, CEFTAZIDIME, MEROPENEM	Its record names the disease	ClinicalTrials.gov
NCT00589693	To Compare Safety and Efficacy of Doripenem Versus Imipenem-Cilastatin in Patients With Ventilator-Associated Pneumonia	Phase 3	274	2012-07-18	Ventilator-Associated Pneumonia	CILASTATIN, DORIPENEM, IMIPENEM	Its record names the disease	ClinicalTrials.gov
NCT02714595	Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens	Phase 3	152	2020-12-17	Healthcare-associated Pneumonia (HCAP), Bloodstream Infections (BSI), Hospital Acquired Pneumonia (HAP), Complicated Urinary Tract Infection (cUTI), Sepsis, Ventilator Associated Pneumonia (VAP)	CEFIDEROCOL	Its record names the disease	ClinicalTrials.gov
NCT00515034	A Safety and Tolerability Study of Doripenem in Patients With Abdominal Infections or Pneumonia	Phase 2	146	2010-06-22	Pneumonia, Ventilator-Associated, Pneumonia, Bacterial, Pneumonia, Abdominal Abscess, Bacterial Infections	DORIPENEM, IMIPENEM	Its record names the disease	ClinicalTrials.gov
NCT01969799	Aerosolized Amikacin and Fosfomycin in Mechanically Ventilated Patients With Gram-negative Pneumonia	Phase 2	143	2017-07-02	Pneumonia, Bacterial	AMIKACIN, FOSFOMYCIN	Its record names the disease	ClinicalTrials.gov
NCT00934934	Candida in the Respiratory Tract Secretions of Critically Ill Patients and The Efficacy of Antifungal Treatment	Phase 2	61	2021-02-01	Ventilator Associated Pneumonia, Respiratory Tract Infection	ANIDULAFUNGIN	Its record names the disease	ClinicalTrials.gov
NCT01570192	Clinical Trials to Reduce the Risk of Antimicrobial Resistance	Phase 2	43	2017-04-20	Bacterial Pneumonia	AMIKACIN, GENTAMICIN, LINEZOLID, MEROPENEM, TOBRAMYCIN, VANCOMYCIN	Its record names the disease	ClinicalTrials.gov
NCT03580044	Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infection Due to MBL-producing Gram-negative Bacteria	Phase 3	15	2024-02-02	Serious Bacterial Infection	AVIBACTAM, AZTREONAM	Its record names the disease	ClinicalTrials.gov
NCT01853982	Study of Intravenous Ceftolozane/Tazobactam Compared to Piperacillin/Tazobactam in Ventilator-Associated Pneumonia	Phase 3	4	2015-06-15	Ventilator-Associated Pneumonia (VAP)	CEFTOLOZANE, TAZOBACTAM	Its record names the disease	ClinicalTrials.gov
NCT04040621	Single-dose PK Study of Ceftazidime-Avibactam In Hospitalized Children Receiving Systemic Antibiotics for Nosocomial Pneumonia	Phase 1	4	2022-09-09	Hospitalized Children With Suspected or Confirmed Nosocomial Pneumonia	AVIBACTAM, CEFTAZIDIME	Its record names the disease	ClinicalTrials.gov

1 to 10 of 52

See all 52 trials

Comparisons in its trials18

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
CAZ-AVI vs Meropenem: serious adverse events	75 of 405	54 of 403	808	NCT01808092	Trial comparisons
Doripenem vs Imipenem-cilastatin: serious adverse events	55 of 115	45 of 112	227	NCT00589693	Trial comparisons
Doripenem vs Imipenem-cilastatin: Clinical Cure Rate at the End-of-treatment (EOT) Visit	36 of 79	50 of 88	167	NCT00589693	Trial comparisons
Doripenem vs Imipenem-cilastatin: 28-day All-cause Mortality Rate	17 of 79	13 of 88	167	NCT00589693	Trial comparisons
Cefiderocol vs Best Available Therapy (BAT): deaths from any cause	34 of 101	9 of 49	150	NCT02714595	Trial comparisons
Cefiderocol vs Best Available Therapy (BAT): serious adverse events	50 of 101	23 of 49	150	NCT02714595	Trial comparisons
Amikacin Fosfomycin Inhalation Solution vs Aerosolized Placebo: serious adverse events	28 of 71	27 of 72	143	NCT01969799	Trial comparisons
Amikacin Fosfomycin Inhalation Solution vs Aerosolized Placebo: Mortality From Day 1 Through Day 28	17 of 71	12 of 71	142	NCT01969799	Trial comparisons
Amikacin Fosfomycin Inhalation Solution vs Aerosolized Placebo: Clinical Relapse Rate	10 of 71	14 of 71	142	NCT01969799	Trial comparisons
Doripenem vs Imipenem-cilastatin: Clinical Cure Rate at the End-of-treatment (EOT) Visit in Patients From Whom at Least 1 of the Gram-negative Qualifying Pneumonia Pathogens (Enterobacteriaceae, P. Aeruginosa, and Acinetobacter Spp) Was Isolated at Baseline	32 of 65	34 of 62	127	NCT00589693	Trial comparisons

1 to 10 of 18

See all 18 comparisons in its trials

Papers from its trials38

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
25583727	RESULT	1	PubMed
19698010	RESULT	1	PubMed
18752007	RESULT	1	PubMed
41269522	DERIVED	1	PubMed
40530972	DERIVED	1	PubMed
38252170	DERIVED	1	PubMed
37700689	DERIVED	1	PubMed
36059138	DERIVED	1	PubMed
35076335	DERIVED	1	PubMed
34871241	DERIVED	1	PubMed

1 to 10 of 38

See all 38 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_1001865

GET https://conductscience.org/api/diseases/v1/EFO_1001865/drugs?page=2

API reference For AI assistants